Analyst Reco. Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
143.3 ^USD	-0.28%		-0.76%	-25.13%

Apr. 08	Sector Update: Health Care Stocks Flat to Higher Premarket Monday	MT
Apr. 08	Sector Update: Health Care	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	Apr. 08
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	Feb. 26
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	Feb. 21
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating	Feb. 16	MT
Goldman Sachs Downgrades Alnylam Pharmaceuticals to Neutral From Buy, Cuts Price Target to $173 From $230	Feb. 16	MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...	Feb. 16
Wolfe Research Initiates Coverage on Alnylam Pharmaceuticals With Peer Perform Rating	Feb. 15	MT
Morgan Stanley Adjusts Alnylam Pharmaceuticals' PT to $176 From $184, Keeps Equalweight Rating	Feb. 13	MT
JPMorgan Adjusts Alnylam Pharmaceuticals' Price Target to $170 From $150, Keeps Neutral Rating	Feb. 01	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $235 From $230, Keeps Outperform Rating	Jan. 03	MT
Wells Fargo Initiates Alnylam Pharmaceuticals With Equalweight Rating, Price Target is $171	Dec. 08	MT
Morgan Stanley Adjusts Price Target on Alnylam Pharmaceuticals to $183 From $175, Maintains Equal-Weight Rating	Nov. 03	MT
RBC Cuts Price Target on Alnylam Pharmaceuticals to $230 From $235, Keeps Outperform Rating	Nov. 03	MT
UBS Adjusts Alnylam Pharmaceuticals Price Target to $253 From $256, Maintains Buy Rating	23-10-24	MT
HC Wainwright Cuts Price Target on Alnylam Pharmaceuticals to $395 From $405, Maintains Buy Rating	23-10-11	MT
Oppenheimer Downgrades Alnylam Pharmaceuticals to Perform From Outperform, Removes $249 Price Target	23-10-11	MT
RBC Cuts Price Target on Alnylam Pharmaceuticals to $235 From $270 Amid Complete Response Letter, Keeps Outperform Rating	23-10-11	MT
Bernstein Cuts Alnylam Pharmaceuticals' Price Target to $218 From $237, Maintains Outperform Rating	23-10-10	MT
Evercore ISI Cuts Alnylam Pharmaceuticals' Price Target to $210 From $252, Maintains Outperform Rating	23-10-10	MT
TD Cowen Adjusts Alnylam Pharmaceuticals' Price Target to $260 From $265, Maintains Outperform Rating	23-10-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Analyst Reco.

Filters